Johnson & Johnson (J&J) has completed its $3.05-billion acquisition of Halda Therapeutics, a clinical-stage bio/pharmaceutical company focused on oral therapies for multiple types of solid tumors, including prostate cancer. The acquisition was announced in November 2025. 

Halda has a proprietary discovery platform, Regulated Induced Proximity Targeting Chimera (RIPTAC), to enable the modular design of RIPTAC therapeutics as a novel heterobifunctional drug modality for precision cancer treatment. Halda’s lead candidate, HLD-0915, is a clinical-stage therapy for prostate cancer. The acquisition also includes several earlier candidates for breast, lung, and multiple other tumor types. Halda’s pipeline and platform may also enable the creation of targeted therapies beyond oncology. 

Source: Johnson & Johnson